Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials.

Francisco Cezar Aquino de Moraes Gustavo de Oliveira AlmeidaVinícius Freire Costa AlvesJonathan N PrianttiGiovanna da Conceição GomesSarah Vitória Bristot CarnevalliThiago MadeiraMaysa Vilbert Carlos Stecca Maria Cristina Figueroa Magalhães Marianne Rodrigues FernandesNey Pereira Carneiro Dos Santos

Published in: Journal of personalized medicine (2024)

Our results show that the addition of CDK4/6 inhibitors is associated with a significant benefit for HR+/HER2- esBC patients in iDFS. More studies and longer follow-up are needed to assess overall survival benefits.

Keyphrases

phase iii
early breast cancer
end stage renal disease
cell cycle
clinical trial
ejection fraction
newly diagnosed
open label
double blind
prognostic factors
stem cells
cell death
cell proliferation
cell therapy